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ABSTRACT 
 
Microsatellite instability (MSI) is a term used to describe the somatic addition or loss of bases 
within repetitive DNA sequences called microsatellites and is characteristic of certain cancer 
types- specifically endometrial cancer (~30% of patients), colorectal cancer (~15% of patients) 
and stomach cancer (~15% of patients). MSI can have prognostic and predictive implications, and 
recently MSI was shown to be a predictor of response to anti-Programmed Death Ligand 1 (PD-
L1) immunotherapy, which has substantially improved outcome in several cancers. Although the 
thyroid is one of the most common cancer sites, the prevalence of MSI in thyroid cancer has not 
been accurately defined.  Previous studies on MSI in thyroid cancer have focused almost 
exclusively on the most common histological subtype, papillary thyroid carcinoma (PTC). Herein 
we have screened for MSI in a large set of thyroid cancer samples representing all major histologic 
subtypes. 
 
Defining MSI status has been standardized by polymerase chain reaction (PCR) of five specific 
microsatellites, and tumors are considered MSI-positive (MSI+) if at least two of the five markers 
show MSI. Using PCR, we screened a total of 191 thyroid cancer cases including: 122 PTC, 35 
follicular thyroid carcinomas (FTC), 20 medullary thyroid carcinomas, and 14 anaplastic thyroid 
carcinomas. MSI was observed in 5% of FTC cases by PCR and validated with 
immunohistochemistry staining of the MMR proteins. A separate cohort of 184 thyroid carcinoma 
cases of various histologies was screen for MSI using a more recent technique based on next-
generation sequencing (NGS). A total of 10 cases were predicted to be MSI by this method, three 
of which were FTCs. 
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The presence of MSI in FTC, even in a small percentage of cases, could have important clinical 
implications. Screening for MSI is already performed for newly diagnosed colorectal cancers in 
Ohio hospitals, as part of the Ohio Colorectal Cancer Prevention Initiative. FTC patients could 
likewise be screened for MSI upon diagnosis, and patients shown to be MSI positive could be 
treated with the remarkable PD-1 immunotherapy. Together, this project will provide a 
comprehensive evaluation of MSI in thyroid cancer.  
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Microsatellites are repetitive DNA sequences of one to five nucleotides that are found throughout 
the genome. There is no well-accepted rule for when a repeat is considered long enough or short 
enough to be classified as a microsatellite, rather than a mini or macrosatellite; repeats as short as 
three units, or as long as several hundred have both been defined as microsatellites1.  
 
In the human genome, whole genome sequencing (WGS) data has revealed as many as 253,000 
microsatellites, and the densities of microsatellites are similar on all chromosomes2. Because 
microsatellites are more susceptible to mutation than non-repetitive DNA sequences, there is 
selective pressure against microsatellites in exons. In addition, the high mutability of 
microsatellites means that the length of most microsatellites is highly variable between individuals 
in the population. This allows microsatellite lengths to serve as a ‘DNA fingerprint’ to facilitate 
identifying DNA.  
 
Mismatch Repair (MMR) 
 
Any mechanism involving the synthesis of new DNA may generate changes in length within 
microsatellites or other repeats, be it from replication, recombination, or repair, however this is 
usually corrected with mismatch repair2. Mismatch repair proteins (MMR) are responsible for 
correcting base substitution mismatches, as well as single-base insertions or deletions (indels) 
during DNA replication. MMR also prevents recombination of divergent DNA sequences, which 
improves genetic stability. MMR can also participate in cell cycle checkpoint control, first by 
recognizing certain forms of DNA damage, then by triggering a response to this damage such as 
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cell cycle arrest3–5. Recent evidence suggests that deficient MMR leads to a disproportionate 
increase of single nucleotide variant mutations in genes, rather than nongenic regions of the 
genome, therefore preferentially protecting genes from mutation6. 
 
MMR proteins were first discovered in prokaryotes, where loss of expression led to an 
accumulation of DNA replication errors and a mutator phenotype. MMR begins by recognizing 
the mismatched base, which can be found structurally due to the resulting distortion of the double 
helix from the mispairing. MMR must also remove the newly synthesized strand containing the 
mismatch and allow for it to be resynthesized; strand discrimination between the correct template 
strand and the incorrect newly synthesized strand is an important feature in MMR systems, 
although the mechanism for strand discrimination is different in prokaryotes, which recognize 
GmeATC on the template strand, than in eukaryotes which lack this type of DNA methylation5.  
 
In E. coli, MMR is well understood and is comprised of three proteins: MutS, MutL, and MutH. 
MutS, an ATPase, binds to the DNA as a homodimer and diffuses along the DNA until it 
recognizes the mismatch. In this conformation, it is ADP bound. Once bound at the mismatch, 
ADP is exchanged for ATP, and MutS can move away from the mismatch. MutL, also an ATPase, 
couples to the activated, mismatch bound MutS. Once MutS becomes ATP bound and can slide 
away from the lesion, the MutL-MutS complex slides along the DNA until it encounters a methyl 
bound MutH. MutH is a methylation-sensitive endonuclease that ensures the repair is limited to 
the newly synthesized DNA strand5,7–9. Once a strand break at the methylation site has been 
generated by MutH, MutS and MutL coordinate recognition of the mismatch site and the break to 
permit loading of DNA helicase II (UvrD) at the break. DNA helicase II unwinds the DNA, and 
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the growing single stranded newly synthesized DNA is degraded by exonucleases. DNA Helicase 
II continues to move towards the mismatch, terminating a variable but short distance past it10,11. 
DNA polymerase III engages with the template strand and conducts repair synthesis, and DNA 
ligase seals the resulting nick4. 
 
Eukaryotes possess multiple MSH proteins (MutS homologs; MSH2-6 in humans), as well as 
MLH proteins (MutL homologues; in humans PMS1, PMS2, MLH1, and MLH3), and the 
mechanism of repair is similar. Rather than a homodimer of MutS binding to the mismatch, MSH2 
and either MSH6 or MSH3 form a dimer (called MutSa with MSH2-MSH6, and MutSb with 
MSH2 and MSH3). In the case of the MutL homologs, MLH1 may dimerize with either PMS2, 
PMS1, or MLH3. Of these three potential MLH1 partners, the MLH1-PMS2 dimer (called MutLa) 
is the best understood. It is known to possess endonuclease activity and interacts with the MutSa/b 
complex12. Eukaryotes lack MutH homologues, and as such MMR is not methyl-directed as in E. 
coli. Instead, eukaryotic MMR is thought to be nick-directed.  In mammals, proliferating cell 
nuclear antigen (PCNA) is co-immunoprecipitated with MSH2, MLH1, and PMS2, which suggests 
that PCNA could play an important role in MMR and perhaps strand discrimination13. Excision is 
less well understood in eukaryotes, but is thought to involve Exonuclease 1 (Exo1), Replication 
Protein-A (RPA), Replication Factor C (RFC), and DNA Polymerase delta (Pol d)4,14. 
 
Microsatellite Instability and MMR in Cancer 
 
Microsatellite instability (MSI) was discovered when researchers who were attempting to map a 
predisposing gene for hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), a 
highly heritable form of colorectal cancer, found that tumor samples in up to 73% of HNPCC 
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patients showed shifts in electrophoretic mobility of the dinucleotide microsatellites used for 
linkage analysis. The authors suggested that replication errors had occurred in these sequences 
during tumorigenesis, and the phenotype was later termed microsatellite instability (MSI)15. The 
original HNPCC predisposing gene that the researchers had been mapping was later discovered to 
be a human homolog of MutS (MSH2), and was found to have somatic as well as germline 
mutations in MSI tumor cells16. MSI tumors were also found to be hypermutated17. MSI was later 
found in other cancer types, and recent studies indicate that MSI is found in as many as 30% of 
endometrial cancers, 15% of colorectal cancers, and 15% of stomach cancers18. 
 
MSI is generally detected by the measurement of polymerase chain reaction (PCR) amplicons 
spanning the microsatellite itself and comparing the resulting amplicon lengths from the tumor 
DNA sample to the corresponding normal tissue DNA sample. A panel of five microsatellites, 
consisting of the mononucleotides BAT25 and BAT26, and the dinucleotides D17S250, D2S123, 
and D5S346, has been standardized for PCR based detection of MSI. A sample is classified as 
MSI if two out of five markers demonstrated instability19,20. Since MSI is due to loss or near loss 
of MMR activity, immunohistochemistry (IHC) staining of MMR proteins provides another, more 
direct detection method. Loss of MSH2 or MLH1 leads to complete loss of MMR. MSH2 is needed 
to stabilize both MSH6 and MSH3, however loss of either MSH6 or MSH3 alone still confers 
some MMR activity. Nonsense mutations in MLH1 show loss of MLH1 as well as PMS2 by IHC12. 
Recent advances in next generation sequencing technologies have allowed for the detection of MSI 
by examining read lengths of the microsatellites covered in the sequencing panel. Examples of 
variant caller software used for MSI detection include MSIseq21,  mSINGS22, MonoSeq23, 
MSIsensor24, and MANTIS25.  
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MMR and Targeted Immunotherapy: the PD-1 Blockade 
Due to their genetic changes, tumor cells can produce antigens that are presented on the cell 
surface, which are different from the antigens presented by non-tumor cells. The adaptive immune 
system possesses anti-tumor activity and can recognize these tumor neo-antigens. However, the 
amplitude of T cell response can be attenuated by inhibitory signals (immune checkpoints). In a 
normal cell, these immune checkpoints prevent autoimmunity, and protect the cells from damage 
when the immune system responds to other infections. In tumors, these immune checkpoints are 
often upregulated and allow the tumor to evade immune system surveillance. As such, targeting 
these immune checkpoint receptors or ligands  is a promising avenue for anti-cancer therapeutics26.   
 
One such example of these immune checkpoints is programmed death 1 (PD-1), and its ligands, 
PD-L1 and PD-L2. In a normal cell, PD-L1 expression limits T cell responses and protects tissues 
from autoimmunity. In tumors, PD-L1 is highly expressed, and is a common feature of the tumor 
microenvironment of solid tumors such as breast, lung, colon, ovarian, melanoma, bladder, 
thyroid, and more. The PD-1 receptor is also often found to be upregulated on tumor infiltrating 
lymphocytes, further contributing to tumor immunosuppression26,27. Pharmacologic inhibition of 
PD-1/PD-L1 interaction restores T cell activity towards tumor cells. PD-1 immunotherapy was 
initially tested in a variety of cancers, with good responses found in melanomas, renal-cell 
carcinomas, and lung tumors. However, out of 33 colorectal cases tested initially, only one patient 
had a response to the treatment28,29. It was later inferred that this patient must have had an MMR 
deficient colorectal cancer (CRC) after another study found remarkable responses in MMR 
deficient CRC cases compared to MMR proficient CRCs30. PD-1 immunotherapy was expanded 
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to 12 different cancer types, all with MMR deficiency, and many patients had durable responses, 
and rapid in vivo production of tumor neoantigen-specific T cell clones31. Using a murine system 
of MMR deficient colorectal, breast, and pancreatic tumors, it was demonstrated that MMR 
deficient tumors had an increased mutational load, dynamic mutational profiles, and continued 
renewal of tumor neoantigens relative to MMR proficient tumors. This robust study functionally 
elucidated the correlation between MMR deficiency (MSI), immune surveillance, and therefore 
response to PD-1 immunotherapy.32 
 
MSI and Thyroid Cancer 
 
Thyroid Cancer is the eighth most common malignancy in the United States, accounting for an 
estimated 56,900 new cases in 2017, as well as 2,000 deaths33. Thyroid cancer has several 
histological subtypes: papillary thyroid carcinoma (PTC, 85% of cases), medullary thyroid 
carcinoma (MTC; 3-5% of cases), follicular thyroid carcinoma (FTC, 2-5% of cases), 
and anaplastic thyroid carcinoma (ATC), a rare and more aggressive variant in approximately 1% 
of cases34. PTCs originate from the follicular cells that produce thyroid hormones, and are 
microscopically characterized by the presence of papillae, while FTCs lack this feature. MTCs 
originate from C cells, also known as parafollicular cells, responsible for producing the hormone 
calcitonin35. ATCs emerge from the follicular cells either de novo, or through accumulation of 
genetic changes in more common thyroid malignancies, such as from PTC cases35,36.  
 
Extensive evidence is lacking for the presence of MSI (and underlying mutations in MMR genes) 
in the thyroid malignancies18,37.  Previous research has primarily focused on PTC, largely 
neglecting other subtypes of thyroid cancer, and the largest study investigating MSI in thyroid 
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cancer to date included only 40 cases. There has been some controversy in the literature regarding 
the percentage of MSI+ thyroid cancers, with different studies reporting  anywhere from 0%-65% 
of cases are MSI+18,38–42. 
 
In this study, we sought to definitively determine the presence of MSI in thyroid cancer. We used 
PCR-based methods to screen 191 thyroid cancer cases (122 PTCs, 35 FTCs, 20 MTCs, and 14 
ATCs). In MSI+ cases, we validated loss of MMR protein expression using IHC staining of MLH1, 
MSH2, MSH6, and PMS2. We separately used the MonoSeq23, variant caller to infer MSI status 
in an independent cohort of 184 thyroid cancer cases that had been previously sequenced using 
NGS methods. Together, this represents the most comprehensive evaluation of MSI in thyroid 
cancer to date.  
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METHODS 
 
Samples: Individuals were recruited from a multidisciplinary thyroid tumor clinic at Ohio State 
University Wexner Medical Center (OSUWMC) and all cases were histologically confirmed as 
either PTC, FTC, MTC or ATC. Recruitment took place in OSUWMC primary care and internal 
medicine clinics. All patients provided written informed consent, completed a questionnaire that 
included demographic, medical and family history information, and donated a blood sample. 
Relevant clinical and pathological data for cases were extracted from the electronic medical record.  
 
The experimental protocols were approved by the Institutional Review Board at the Ohio State 
University. Experiments were carried out in accordance with the approved guidelines. 
 
DNA Extraction: The DNA samples from primary thyroid tumor tissue were snap frozen in liquid 
nitrogen after biopsy, digested with proteinase K, and extracted using phenol-chloroform methods. 
For   six ATC cases and 30 FTC cases, DNA was extracted from paraffin cores using phenol-
chloroform or the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). In the three cases 
that lacked adjacent normal thyroid tissue, skeletal muscle tissue was used for two cases and lymph 
node tissue was used for one case. 
 
MSI PCR testing: We designed marker specific PCR primers for amplification of four 
microsatellites (BAT25, BAT26, D17S250, and D2S123).  A fluorescein amidite (FAM) M13 
universal forward primer was used to label PCR-products as previously described43, with the 
exception of the BAT25 forward primer, for which we used a locus-specific hexachloro-
fluorescein phosphoramidite (HEX) labeled primer. Capillary electrophoresis was performed with 
Microsatellite Instability is Present in a Subset of Follicular Thyroid Carcinomas 
Luke K. Genutis 13 
an ABI PRISM® 3730 DNA Analyzer to detect strand-slippage mutations indicative of MSI. 
Malignant samples were compared with their germ line DNA, a negative experimental control, 
and three MSI+ colorectal cancer control samples. 
 
IHC Staining: Blocks for two putative MSI+ FTC cases were reviewed and stained with 
antibodies against MLH1, MSH2, MSH6, and PMS2 using 3,3'-Diaminobenzidine (DAB) and 
hematoxylin. An MMR proficient FTC case served as a positive control.  
 
NGS Analysis: A total of 184 thyroid cancer cases were selected to be sequenced using the 
oncomine v3 targeted sequencing panel. Sequencing was performed using a SOLiD sequencer. 
The resulting NGS data were analyzed using the Monoseq23 variant caller to infer MSI status. 
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RESULTS 
 
We determined the MSI status of a sizable cohort of thyroid cancer samples with histologic 
subtypes representative of a typical patient population (122 PTCs, 35 FTCs, 20 MTCs, and 14 
ATCs). The cases were screened with PCR amplicons spanning the microsatellites BAT25, 
BAT26, D17S250, and D2S123 by comparing microsatellite lengths between the tumors and 
matched normal DNAs (Table 1 and Figure 1). Out of 191 cases screened with this method, two 
FTC cases (FTC-267 and FTC-727) demonstrated MSI (Table 2). We confirmed loss of DNA 
MMR in these samples by IHC staining for MLH1, MSH2, MSH6, and PMS2. FTC-267 showed 
a loss of MSH2 and MSH6, and FTC-727 had a loss of MLH1 and PMS2 (Figure 2). These results 
are consistent with the findings that loss of MLH1 expression tends to be found with loss of PMS2, 
and loss of MSH2 expression is found with loss of MSH6 expression12,44. Adequate DNA was 
available for FTC-267 and allowed us to investigate mutations underlying the MMR defect. FTC-
267 was whole-exome sequenced and found to have a hemizygous p.W345* 
(NM_000251.2:c.1035G>A) nonsense mutation in MSH2 (Figure 3). This mutation would lead to 
a premature stop codon in the protein sequence, and therefore a truncated and quickly degraded 
protein. This is consistent with our IHC data for this sample, showing a loss of MSH2 and MSH6 
expression.  
 
We next sought to validate our discovery efforts in another cohort using next generation 
sequencing (NGS) methods (Figure 4a). The variant caller MonoSeq23 was used with a separate 
cohort of 184 thyroid carcinomas of various histologies (Figure 4b) that were previously 
sequenced for a targeted panel containing 29 microsatellites. We used MonoSeq23 to assign an 
MSI likelihood score to each sample, and samples with a score >20 are predicted to be MSI. Out 
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of 184 thyroid carcinoma cases of mixed histologies, 10 cases were predicted to be MSI (Figure 
4b). Notably, FTC cases accounted for 30% of the total MSI cases, despite FTC representing 5% 
of the cohort. Furthermore, one of these cases, NGS 141, had hyper mutability consistent with 
defective MMR (Figure 5).   
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DISCUSSION AND FUTURE DIRECTIONS 
 
Our results indicate the strongest evidence for MSI in thyroid cancer to date. We believe that 
because we found he MSI is mainly in FTC cases, it may have been overlooked in previous studies 
focused on PTC cohorts that report MSI is absent in thyroid cancer39.  
 
We speculate that previous studies which reported a high incidence of MSI in thyroid cancer were 
reporting technical false positives. These previous reports varied greatly in the microsatellites 
chosen, did not use the ‘gold standard’ Bethesda panel of PCR primers40–42, and relied on 
polyacrylamide gels to determine PCR product size, rather than capillary electrophoresis. More 
recent studies on the prevalence of MSI in thyroid cancer have been conducted using NGS 
methods. One study looked at PTC cases and found ~2% of cases to be MSI+18, while another 
study looked at late stage thyroid carcinomas, a phenotype rare in PTC but common in other 
histologies, and found the rate of MSI to be as high as 3% 31.  
 
Herein we found MSI to be present in 5% of FTC cases, and absent in all other screened histologies 
(Table 1). We were able to confirm MMR deficiency at the protein level in these cases and showed 
that the tumor with loss of MSH2 and MSH6 harbored a hemizygous nonsense mutation in MSH2. 
(Figures 2 and 3). NGS analysis permitted a way to validate our PCR results using a separate 
cohort. NGS based detection of MSI is similar to the traditional PCR-based detection, in that MSI 
is detected by measuring the distribution of different length microsatellites in the reads that span 
each microsatellite. Ten samples were putatively identified as MSI by the MonoSeq23 variant 
caller, and interestingly, one of these cases was a  widely invasive FTC, which is consistent with 
the idea that MMR deficient tumors can evade immune surveillance 31,32,45.  
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Our results imply that clinical screening of FTC cases for MMR deficiency could uncover some 
patients who are candidates for MSI-directed immune checkpoint inhibitor therapies. Notably, all 
Ohio CRC patients are already screened for MSI through the Ohio Colorectal Cancer Prevention 
Initiative (https://clinicaltrials.gov/ct2/show/NCT01850654), and we argue for extending this 
screening network to Ohio FTC patients. Future work validating these results in more FTC cases 
will help to more accurately define the overall prevalence of MSI in FTC.  
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FIGURES AND TABLES 
 
Table 1. Microsatellite PCR Primers 
 











PCR based microsatellite detection was facilitated using an M13 tagged universal primer to 
permit fluorescent detection with capillary electrophoresis. PCR protocol was according to 
previous methods43.  
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Figure 1. PCR Based Detection of MSI 
 
Fig. 1 Electropherograms of Microsatellite PCR markers 
were compared between tumor DNA and corresponding 
normal tissue DNA for each case. An example of a 
strand-slippage mutation in BAT25 is shown. The 
amplified tumor DNA has additional shorter 
microsatellites, creating an overall bimodal distribution of 
amplicon lengths, when compared to the paired germline 



















Table 2. Total Results of the PCR Screen 
 
Histology Total Cases Unstable Cases % Unstable 
Anaplastic Thyroid Carcinoma (ATC) 14 0 - 
Follicular Thyroid Carcinoma (FTC) 35 2 5.7 
Medullary Thyroid Carcinoma (MTC) 20 0 - 
Papillary Thyroid Carcinoma (PTC) 122 0 - 
Total Cases 191   
 
Table 2 We screened 191 cases for MSI using the microsatellite markers BAT25, BAT26, 
D17S250 and D2S123. A total of two FTCs were found to be MSI by this PCR-based detection 
method, with the case FTC 267 was found to be unstable at BAT25 and D2S123, and FTC 727 
was unstable at all four markers tested. 
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Figure 2. IHC staining of MSI FTCs by PCR 
 
 
Fig. 2 Immunohistochemistry (IHC) staining of the MMR proteins MLH1, MSH2, MSH6, 
PMS2, and hemoxylin and eosin (HE). MMR proficient cells for each stain have brown nuclei, 
while MMR deficient cells have only hematoxylin staining in the nuclei (blue). Sample FTC-267 
showed a loss of MSH2 and MSH6, while sample FTC-727 showed a loss of MLH1 and PMS2. 
An MMR proficient tumor sample serves as the positive control for the MMR protein staining 
(+Control).  
  
















   









+Control Tumor   Normal FTC-727 
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Figure 3. Targeted sequencing validation of underlying MMR mutation. 
 
 
Fig. 3 DNA was available for 
one of the MSI+ FTCs. 
Whole exome sequencing was 
performed and revealed an 
MSH2 mutation underlying 
the MSI.  
 
Whole exome sequencing of 
paired tumor and normal 
DNA from FTC-267, 
visualized by integrated 
genomics viewer. The tumor 
DNA (top) has a G>A 
transition that is not evident in 
the normal DNA (bottom). 
This transition is a nonsense 
mutation (p. W345*), and 
loss-of-heterozygosity can be 
inferred because the mutation 
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Figure 4. NGS based screen of a validation cohort.  
 
Fig 4. The MonoSeq variant caller was used to detect MSI in SOLiD sequencing data from 184 
thyroid carcinoma cases of various histologies. A. Distribution of MSI likelihood score for all 
screened cases in this cohort. Cases with scores >20 are predicted to be MSI+. B. Histological 










FTC 10 3 30%
PTC 73 3 4%
ATC 36 2 6%
MTC 45 1 2%
Hurtle Cell 3 0 0%
Poorly Diff. 17 1 6%
Total 184 10 5%
MSI Likelihood Score  
Distribution of the Number of Unstable Loci 
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Figure 5. Mutational profile of the 10 putative MSI cases by NGS 
Case Diagnosis Mutations 
NGS151 ATC 3 
NGS 188 ATC 2 
NGS 032 FTC-WI 1 
NGS 141 FTC-WI 9 
NGS 142 FTC-WI 1 
NGS 157 MTC 1 
NGS 75 PD 2 
NGS 13 PTC 2 
NGS 101 PTC 1 
NGS 185 PTCfv/PD 0 
 
Fig. 5 Mutational landscape of the 10 putative MSI thyroid carcinoma case. 30% of cases are 
FTC and widely invasive. Of these, NGS-141 is also hypermutated with a mutational load of 9 
mutated genes covered by the oncomine panel. ATC= Anaplastic thyroid carcinoma; FTC-
WI=follicular thyroid carcinoma, widely invasive; MTC=medullary thyroid carcinoma; 
PD=poorly differentiated thyroid carcinoma; PTC=papillary thyroid carcinoma; 
PTCfv=follicular variant.  
